Clinical Edge Journal Scan

Postmastectomy implants did not increase risk for squamous cell carcinoma in BC patients


 

Key clinical point: The incidence rate of squamous cell carcinoma (SCC) was extremely low and, hence, of minimal public health concern in patients with non-SCC breast cancer (BC) or carcinoma in situ who underwent implant-based reconstruction.

Major finding: Only 1 woman was diagnosed with SCC after 52 months of BC diagnosis. The incidence rate of SCC after implant-based reconstruction was extremely low (2.37 per million person-years) and was not significantly higher in women with BC than in the general population (standardized incidence ratio 2.33; 95% CI 0.06-13.0).

Study details: Findings are from a cohort study including 56,785 women with BC or carcinoma in situ who underwent cancer-directed mastectomy with implant reconstruction.

Disclosures: This study was supported by the US National Cancer Institute. Some authors declared receiving personal fees or grants or having other ties with several sources.

Source: Kinslow CJ et al. Risk of squamous cell carcinoma of the breast following postmastectomy implant reconstruction in women with breast cancer and carcinoma in situ. JAMA Surg. 2023 (Apr 19). Doi: 10.1001/jamasurg.2023.0262

Recommended Reading

Number of cancer survivors with functional limitations doubled in 20 years
MDedge Hematology and Oncology
BMI has greater impact on survival in younger breast cancer patients
MDedge Hematology and Oncology
T-DXd for HER2-low BC: Analysis confirms adverse effects
MDedge Hematology and Oncology
Patritumab deruxtecan shows promise for breast cancer patients
MDedge Hematology and Oncology
Risk for breast cancer reduced after bariatric surgery
MDedge Hematology and Oncology
Atezolizumab is associated with enhanced response in triple-negative breast cancer
MDedge Hematology and Oncology
Genomic assay changes minds on HER2+ BC treatment
MDedge Hematology and Oncology
HR+ early BC patients could briefly interrupt endocrine therapy to attempt pregnancy
MDedge Hematology and Oncology
Anthracycline+taxane combo reduces BC recurrence more effectively than either drug alone
MDedge Hematology and Oncology
Better lifestyle index scores associated with improved mortality and disease recurrence in high-risk BC
MDedge Hematology and Oncology